This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Asia: Oligonucleotide & Peptide Therapeutics Scientific Forum
See You Next Year! 26-28 Feb, 2025
Westin Miyako KyotoKyoto, Japan

Syncrest Inc


As a joint venture company between Otsuka and Yokogawa, SynCrest delivers a one-stop service for TIDES-based therapeutics, from library synthesis and process development for drug discovery through to manufacturing of experimental medicine for clinical studies, support for new product releases, and on-demand commercial manufacturing. We also deliver more than 100 kinds of natural/unnatural amidites and amino acids with high quality and short lead time.Typically, we can introduce fluorine in peptide and nucleotide compounds in various positions. SynCrest also developed an industry-leading continuous flow synthesis method with in-line measurement that enables non-destructive, high-precision measurements in real time, providing rapid, highly efficient, and high-quality manufacturing to accelerate a wide range of exploratory and drug discovery research. All manufacturing is carried out at SynCrest’s Naruto Plant. It is the first multi-purpose, multi-product plant in the country to utilize the continuous flow synthesis method while being GMP-compliant for highly potent substances (OEL Category 4).